LOGIN  |  REGISTER
Amneal Pharmaceuticals
Recursion

Accolade To Present at Upcoming Investor Conferences

January 02, 2024 | Last Trade: US$3.56 0.07 2.01

SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the following upcoming investor conferences:

  • 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 11 at 7:30am PT
  • 26th Annual Needham Growth Conference in New York on Thursday, January 18 at 3:00pm ET

A webcast of these events will be available at ir.accolade.com and a replay will be available for 90 days.

About Accolade, Inc.

Accolade (Nasdaq: ACCD) is a Personalized Healthcare company that provides millions of people and their families with exceptional healthcare experiences so they can live their healthiest lives. Accolade’s employer, health plan, and consumer solutions combine virtual primary care and mental health, expert medical opinion, and best-in-class care navigation. These offerings are built on a platform that is engineered to care through predictive engagement of population health needs, proactive care that improves outcomes and cost savings, and by addressing barriers to access and continuity of care. Accolade consistently receives consumer satisfaction ratings of over 90%. For more information, visit accolade.com. Follow us on LinkedInTwitter, Instagram and Facebook.

Investor Contact:

Todd Friedman, Investor Relations, This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB